AAAAAA

   
Results: 1-11 |
Results: 11
Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of thecommon IVS14+1G > A mutation causing DPD deficiency
Authors: van Kuilenburg, ABP Muller, EW Haasjes, J Meinsma, R Zoetekouw, L Waterham, HR Baas, F Richel, DJ van Gennip, AH
Citation: Abp. Van Kuilenburg et al., Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of thecommon IVS14+1G > A mutation causing DPD deficiency, CLIN CANC R, 7(5), 2001, pp. 1149-1153
A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer
Authors: Skovsgaard, T Davidson, NGP Piccart, MJ Richel, DJ Bonneterre, J Cirkel, DT Barton, CM Knight, S
Citation: T. Skovsgaard et al., A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer, ANN ONCOL, 12(9), 2001, pp. 1255-1257
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel
Authors: Malingre, MM Richel, DJ Beijnen, JH Rosing, H Koopman, FJ Huinink, WWTB Schot, ME Schellens, JHM
Citation: Mm. Malingre et al., Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel, J CL ONCOL, 19(4), 2001, pp. 1160-1166
Surgery, radiotherapy, and chemotherapy for esophageal carcinoma
Authors: van Lanschot, JJB Gonzalez, DG Richel, DJ
Citation: Jjb. Van Lanschot et al., Surgery, radiotherapy, and chemotherapy for esophageal carcinoma, CURR OPIN G, 17(4), 2001, pp. 400-405
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
Authors: van Kuilenburg, ABP Haasjes, J Richel, DJ Zoetekouw, L Van Lenthe, H De Abreu, RA Maring, JG Vreken, P van Gennip, AH
Citation: Abp. Van Kuilenburg et al., Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene, CLIN CANC R, 6(12), 2000, pp. 4705-4712
Highly purified CD34(+) cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients
Authors: Richel, DJ Johnsen, HE Canon, J Guillaume, T Schaafsma, MR Schenkeveld, C Hansen, SW McNiece, I Gringeri, AJ Briddell, R Ewen, C Davies, R Freeman, J Miltenyi, S Symann, M
Citation: Dj. Richel et al., Highly purified CD34(+) cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients, BONE MAR TR, 25(3), 2000, pp. 243-249
A new four-color flow cytometric assay to detect apoptosis in lymphocyte subsets of cultured peripheral blood cells
Authors: Hasper, HJ Weghorst, RM Richel, DJ Meerwaldt, JH Olthuis, FMFG Schenkeveld, CEI
Citation: Hj. Hasper et al., A new four-color flow cytometric assay to detect apoptosis in lymphocyte subsets of cultured peripheral blood cells, CYTOMETRY, 40(2), 2000, pp. 167-171
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
Authors: Nabholtz, JM Senn, HJ Bezwoda, WR Melnychuk, D Deschenes, L Douma, J Vandenberg, TA Rapoport, B Rosso, R Trillet-Lenoir, V Drbal, J Molino, A Nortier, JWR Richel, DJ Nagykalnai, T Siedlecki, P Wilking, N Genot, JY Hupperets, PSGJ Pannuti, F Skarlos, D Tomiak, EM Murawsky, M Alakl, M Riva, A Aapro, M
Citation: Jm. Nabholtz et al., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy, J CL ONCOL, 17(5), 1999, pp. 1413-1424
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
Authors: Herben, VMM Panday, VRN Richel, DJ Schellens, JHM van der Vange, N Rosing, H Beusenberg, FD Hearn, S Doyle, E Beijnen, JH Huinink, WWT
Citation: Vmm. Herben et al., Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer, J CL ONCOL, 17(3), 1999, pp. 747-755
Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma
Authors: Lokhorst, HM Sonneveld, P Cornelissen, JJ Joosten, P Kooy, MV Meinema, J Nieuwenhuis, HK van Oers, MHJ Richel, DJ Segeren, CN Veth, G Verdonck, LF Wijermans, PW
Citation: Hm. Lokhorst et al., Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma, BONE MAR TR, 23(4), 1999, pp. 317-322
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma
Authors: Segeren, CM Sonneveld, P van der Holt, B Baars, JW Biesma, DH Cornellissen, JJ Croockewit, AJ Dekker, AW Fibbe, WE Lowenberg, B Kooy, MV van Oers, MHJ Richel, DJ Schouten, HC Vellenga, E Verhoef, GEG Wijermans, PW Wittebol, S Lokhorst, HM
Citation: Cm. Segeren et al., Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma, BR J HAEM, 105(1), 1999, pp. 127-130
Risultati: 1-11 |